ReproCELL Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

ReproCELL şirketinin toplam hissedar öz sermayesi ¥8.7B ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥9.4B ve ¥681.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥5.17b
Eşitlik	JP¥8.74b
Toplam yükümlülükler	JP¥681.00m
Toplam varlıklar	JP¥9.42b

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17

Recent updates

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Aug 05

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Feb 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4978 'nin kısa vadeli varlıkları ( ¥6.0B ) kısa vadeli yükümlülüklerini ( ¥642.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4978 şirketinin kısa vadeli varlıkları ( ¥6.0B ) uzun vadeli yükümlülüklerini ( ¥39.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4978 borçsuzdur.

Borcun Azaltılması: 4978 şirketinin 5 yıl önce borç/öz sermaye oranı 1.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4978 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 4978 serbest nakit akışı her yıl % 19.9 oranında tarihsel oranda büyümeye devam ederse 3 yıldan fazla bir süre için yeterli nakit akışına sahip olur

ReproCELL Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Recent updates

Second quarter 2025 earnings released: JP¥0.31 loss per share (vs JP¥0.14 loss in 2Q 2024)

New minor risk - Share price stability

ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024

First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024)

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

New minor risk - Share price stability

ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024

New minor risk - Shareholder dilution

New minor risk - Profitability

ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 20%

ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023

Forecast to breakeven in 2025

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023

Consensus estimates of losses per share improve by 56%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023

Price target decreased to JP¥300

No independent directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

ReproCELL Incorporated to Report Q1, 2023 Results on Aug 10, 2022

ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

No independent directors

ReproCELL Incorporated to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021)

ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm

Consensus EPS estimates increase to -JP¥5.46

Forecast to breakeven in 2024

ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm

Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020)

ReproCELL Incorporated to Report Fiscal Year 2021 Results on May 14, 2021

New 90-day low: JP¥384

Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020)

Revenue and earnings beat expectations

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

New 90-day high: JP¥449

ReproCELL Incorporated to Report Q3, 2021 Results on Feb 12, 2021

Second quarter 2021 earnings released: JP¥2.20 loss per share

New 90-day low: JP¥373

ReproCELL Incorporated to Report Q2, 2021 Results on Nov 12, 2020

First quarter earnings released

Full year earnings released - JP¥14.26 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin